The Estimation of First-Phase Insulin Secretion by Using Components of the Metabolic Syndrome in a Chinese Population
Table 1
Demographic data of the study and external validation groups.
Study group
Ext. val. group
value
140
46
Sex (male/female)
69/71
25/21
0.552
Age (y)
50.7 ± 13.5
50.8 ± 14.7
0.910
Body mass index (kg/m2)
25.2 ± 3.9
25.8 ± 5.1
0.366
Systolic blood pressure (mmHg)
121.5 ± 13.0
118.3 ± 16.2
0.186
Diastolic blood pressure (mmHg)
76.3 ± 8.0
73.4 ± 7.7
0.076
Triglyceride (mmol/L)
1.3 ± 0.6
1.5 ± 0.6
0.112
HDL-C (mmol/L)
1.1 ± 0.3
1.1 ± 0.4
0.350
Fasting plasma glucose (mmol/L)
7.8 ± 2.8
7.5 ± 3.0
0.540
Fasting plasma insulin (pmol/L)
30.5 (12.2–61.3)
27.6 (14.4–62.0)
0.353
First-phase insulin secretion (U/min)
115.0 (23.5–426.4)
114.9 (24.4–430.4)
0.822
Insulin sensitivity (10−4⋅min−1⋅pmol−1⋅L−1)
1.274 (0.5–3.4)
1.6 (0.3–3.3)
0.501
Disposition index
87.8 9 (20.3–900.8)
95.3 (17.0–408.7)
0.830
Glucose effectiveness (10−2⋅dL⋅min−1⋅kg−1)
0.016 ± 0.010
0.015 ± 0.010
0.314
HOMA-IR
1.7 (0.6–3.1)
1.7 (0.7–3.1)
0.615
HOMA-β
22.1 (6.9–83.0)
20.0 (8.5–92.0)
0.334
Data are expressed as mean ± SD or median (interquartile range). Ext. val. group: external validation group. HDL-C: high-density lipoprotein cholesterol; HOMA-IR and HOMA-: homeostasis model assessment of insulin resistance and -cell function.
